Matthew K. Fust - 09 Jun 2026 Form 4 Insider Report for Atara Biotherapeutics, Inc. (ATRA)

Reporting relationship: Director
Issuer ticker: ATRA
Reported as of: 09 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Jun 2026, 16:36:58 UTC
Prior SEC filing: 29 May 2026
Next SEC filing: 22 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ John Chao, Attorney-in-Fact for Matthew Fust

Key filing fact

Matthew K. Fust filed Form 4 for Atara Biotherapeutics, Inc. (ATRA) on 11 Jun 2026.

Key facts

This page summarizes Matthew K. Fust's Form 4 filing for Atara Biotherapeutics, Inc. (ATRA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 11 Jun 2026, 16:36.

Change

Previous filing in this sequence was filed on 29 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001397266 Primary reporting owner

Fust Matthew K

Relationship: Director
Address: C/O ATARA BIOTHERAPEUTICS, INC., 1280 RANCHO CONEJO BOULEVARD, THOUSAND OAKS
Signature: /s/ John Chao, Attorney-in-Fact for Matthew Fust
Signature date: 11 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ATRA transaction

Common Stock

Award

Transaction value
Shares: +12,000
Change %: +66%
Price: $0.000000^*
Shares after: 30,188
Date: 09 Jun 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

These restricted stock units shall vest on the earlier of June 9, 2027 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service.